Honma, Y.; Shibata, M.; Ikemi, M.; Yoshitomi, K.; Shinohara, N.; Ogino, N.; Oe, S.; Miyagawa, K.; Abe, S.; Harada, M.
Usefulness of the Early Increase of Peripheral Blood Lymphocyte Count in Predicting Clinical Outcomes for Patients with Advanced Hepatocellular Carcinoma Treated with Durvalumab Plus Tremelimumab. Cancers 2025, 17, 1274.
https://doi.org/10.3390/cancers17081274
AMA Style
Honma Y, Shibata M, Ikemi M, Yoshitomi K, Shinohara N, Ogino N, Oe S, Miyagawa K, Abe S, Harada M.
Usefulness of the Early Increase of Peripheral Blood Lymphocyte Count in Predicting Clinical Outcomes for Patients with Advanced Hepatocellular Carcinoma Treated with Durvalumab Plus Tremelimumab. Cancers. 2025; 17(8):1274.
https://doi.org/10.3390/cancers17081274
Chicago/Turabian Style
Honma, Yuichi, Michihiko Shibata, Masatoshi Ikemi, Kengo Yoshitomi, Nobuhiko Shinohara, Noriyoshi Ogino, Shinji Oe, Koichiro Miyagawa, Shintaro Abe, and Masaru Harada.
2025. "Usefulness of the Early Increase of Peripheral Blood Lymphocyte Count in Predicting Clinical Outcomes for Patients with Advanced Hepatocellular Carcinoma Treated with Durvalumab Plus Tremelimumab" Cancers 17, no. 8: 1274.
https://doi.org/10.3390/cancers17081274
APA Style
Honma, Y., Shibata, M., Ikemi, M., Yoshitomi, K., Shinohara, N., Ogino, N., Oe, S., Miyagawa, K., Abe, S., & Harada, M.
(2025). Usefulness of the Early Increase of Peripheral Blood Lymphocyte Count in Predicting Clinical Outcomes for Patients with Advanced Hepatocellular Carcinoma Treated with Durvalumab Plus Tremelimumab. Cancers, 17(8), 1274.
https://doi.org/10.3390/cancers17081274
